Werewolf Therapeutics, Inc. HOWL
At closeNov 3, 2026, 4:00 PM EST
After hours · Nov 3, 4:00 PM ET
- YTD
- +68.77%
- 1 year
- -18.32%
- Market cap
- 52.00M
- Revenue (ttm)
- 3.39M
- EPS (ttm)
- -0.73
- Shares out
- 44.56M
- Forward P/E
- -0.86
- YTD return
- +68.77%
- 1-year return
- -18.32%
- Volume
- 232.24K
- Avg volume
- 6.69M
- Open
- 1.04
- Previous close
- 1.05
- Day's range
- 1.03 – 1.08
- 52-week range
- 0.27 – 1.30
- Beta
- 0.41
- Price target
- 12.00 (+1021.5%)
- Earnings date
- Aug 8, 2024
2Y -1.21 (-53.54%)
Key statistics
- Enterprise value
- -15.19M
- PEG ratio
- 0.00
- Price / sales
- 20.66
- Price / book
- 0.77
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -27.67M
- Total cash
- 122.83M
- Total debt
- 36.78M
- Return on equity
- -61.56%
- Short % of float
- 4.67%
- 50-day average
- 2.11
- 200-day average
- 3.31
Analyst view
- Target (low)
- 8.00
- Target (mean)
- 12.00
- Target (high)
- 15.00
- Strong buy2
- Buy4
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 8, 2024
Expected Aug 8, 2024. Consensus EPS estimate -0.275.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -0.41 | -0.38 | +0.03 | +7.32% |
| Aug 8, 2024 | Jun 1, 2024 | -0.38 | -0.43 | -0.05 | -13.16% |
| Aug 8, 2024 | Jun 1, 2024 | -0.38 | — | — | — |
| May 3, 2024 | Mar 1, 2024 | -0.35 | -0.39 | -0.04 | -11.43% |
| May 3, 2024 | Mar 1, 2024 | -0.35 | — | — | — |
| Mar 7, 2024 | Dec 1, 2023 | -0.43 | -0.33 | +0.10 | +23.26% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 19, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jul 2, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 26, 2024 | JMP Securities | reit | Market Outperform | Market Outperform |
| Jun 26, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 4, 2024 | JMP Securities | reit | Market Outperform | Market Outperform |
| Jun 3, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About Werewolf Therapeutics, Inc.
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- werewolftx.com
News
Werewolf Therapeutics To Present Two Posters On WTX-124, WTX-330 Data At Upcoming SITC 2026 Annual Meeting 
Werewolf Therapeutics Selected for Oral Presentation and to Present Posters at the Society for Immunotherapy of Cancer's (SITC) 2026 Annual Meeting 
12 Health Care Stocks Moving In Tuesday's After-Market Session 
Werewolf Therapeutics (HOWL) Upgraded to Strong Buy: Here's Why 
New Strong Buy Stocks for October 9th 
Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Stock Has Average Target Price of $4.00 According to Analysts 
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Werewolf Therapeutics, Inc. (Nasdaq – HOWL), Beazer Homes USA, Inc. (NYSE – BZH), Lantheus Holdings Inc. (Nasdaq – LNTH), MarketAxess Holdings Inc. (Nasdaq – MKTX) 
Are MKTX, HOWL, PSNL Obtaining Fair Deals for their Shareholders? 
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Personalis, Inc. (Nasdaq – PSNL), Werewolf Therapeutics, Inc. (Nasdaq – HOWL), Beazer Homes USA, Inc. (NYSE – BZH), MarketAxess Holdings Inc. (Nasdaq – MKTX) 
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Werewolf Therapeutics, Inc. (Nasdaq – HOWL), Beazer Homes USA, Inc. (NYSE – BZH), MarketAxess Holdings Inc. (Nasdaq – MKTX), CBIZ, Inc. (NYSE – CBZ)
Your note
Sign in to keep a note on HOWL — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Jan 5, 2023 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| RA Capital Management, L.P. | 13.79% | 6,144,881 | 9.65M | Sep 29, 2024 |
| MPM Asset Management, LLC | 9.61% | 4,284,172 | 6.73M | Sep 29, 2024 |
| Pfm Health Sciences, Lp | 7.63% | 3,398,747 | 5.34M | Sep 29, 2024 |
| MPM BioImpact Capital LLC | 5.36% | 2,388,011 | 3.75M | Sep 29, 2024 |
| Bank of America Corporation | 4.83% | 2,153,717 | 3.38M | Sep 29, 2024 |
| Adage Capital Partners GP L.L.C. | 4.49% | 2,000,594 | 3.14M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.80% | 800,282 | 1.26M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 1.52% | 676,891 | 1.06M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.88% | 392,161 | 615.69K | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 0.70% | 310,654 | 487.73K | Aug 30, 2024 |
| iShares Russell 2000 Value ETF | 0.48% | 211,769 | 332.48K | Oct 30, 2024 |
| Fidelity Extended Market Index Fund | 0.38% | 171,305 | 268.95K | Oct 30, 2024 |